[Phase II trial of an ambulatory treatment with 5-fluorouracil administered by continuous perfusion combined with vindesine and cyclophosphamide].
Thirty-four patients with histologically proven metastatic breast cancer, were included in this phase II trial. They were given a five day course of continuous infusion of 5 fluoro-uracile at the daily dose of 500 mg/m2 associated with vindesine 2 mg/m2 on day 2 and 5, cyclophosphamide 300 mg/m2 on day 2 and 5. The treatment was repeated every 15 days after haematological and biological assay. Twenty-six patients were objectively resistant to previous cytotoxic chemotherapy including adriamycin and 6 patients had recently received adjuvant therapy. A major objective response was observed in 17 cases (50%) (4 complete responses, 13 responses greater than 50%) and a response less than 50% in 7 cases. The median duration of response is over 8 months. After 8 months of median follow-up, the median of survival is not defined.